首个抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动
April 06, 2020 07:00 ET
|
Yiviva
—— 利用整合系统生物学方法，由耶鲁大学郑永齐教授和医起共同开发的首个抗肿瘤候选植物药 中国上海，美国纽约, April 06, 2020 (GLOBE NEWSWIRE) -- 生物制药创新企业医起医药科技有限公司（Yiviva Inc.），在2020年初正式启动了YIV-906联合索拉非尼治疗乙型肝炎相关性肝细胞癌（HCC）的一线疗法IIb期研究，并于今年三月迎来了第一位受试者。 ...
Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular Carcinoma
April 06, 2020 07:00 ET
|
Yiviva
- First-in-class oncology therapeutic candidate YIV-906 applies an integrative systems biology approach -- Global study to evaluate efficacy, safety, and quality of life in patients with hepatitis...
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
January 13, 2020 02:00 ET
|
Adaptimmune Therapeutics plc
- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers - - Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and...
Delcath Systems Announces Postponement of Reverse Stock Split
October 22, 2019 07:27 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Auransa Presents New Preclinical Data on AU-409, a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma
September 23, 2019 08:05 ET
|
Auransa
PALO ALTO, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical...
Auransa to Present New Data on AU-409, a Novel, AI-Generated Drug Candidate for the Treatment of Hepatocellular Carcinoma, at the 13th Annual Conference of the International Liver Cancer Association
September 16, 2019 08:05 ET
|
Auransa
PALO ALTO, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical...
Cancer Immunotherapy Market To Reach USD 242.86 Billion By 2026 | Reports And Data
July 17, 2019 11:02 ET
|
Reports and Data
New York, July 17, 2019 (GLOBE NEWSWIRE) -- Increasing demand for cancer immunotherapy in hospitals, cancer research centers, and clinics coupled with high investment in R&D of cancer...
Interventional Oncology Market Worth $1,506.3 Million by 2025- Exclusive Report by Meticulous Research®
July 15, 2019 09:16 ET
|
Meticulous Market Research Pvt. Ltd.
London, July 15, 2019 (GLOBE NEWSWIRE) -- According to the new market research report “Interventional oncology Market by Procedure [Embolization (TARE, TACE), Ablation (Thermal Ablation (Microwave,...
Carcinoembryonic Antigen Market will expand at 6.7% CAGR to hit $3 bn by 2024: Global Market Insights, Inc.
January 15, 2019 05:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Japan dominated the Asian carcinoembryonic antigen market and was valued around USD 74.6 million in the year 2017. Growing awareness about...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
October 04, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...